Christie B. Palmer
Atypical opioid receptors: unconventional biology and therapeutic opportunities
Palmer, Christie B.; Meyrath, Max; Canals, Meritxell; Kostenis, Evi; Chevigné, Andy; Szpakowska, Martyna
Authors
Max Meyrath
Professor MERITXELL CANALS M.CANALS@NOTTINGHAM.AC.UK
PROFESSOR OF CELLULAR PHARMACOLOGY
Evi Kostenis
Andy Chevigné
Martyna Szpakowska
Abstract
Endogenous opioid peptides and prescription opioid drugs modulate pain, anxiety and stress by activating four opioid receptors, namely μ (mu, MOP), δ (delta, DOP), κ (kappa, KOP) and the nociceptin/orphanin FQ receptor (NOP). Interestingly, several other receptors are also activated by endogenous opioid peptides and influence opioid-driven signaling and biology. However, they do not meet the criteria to be recognized as classical opioid receptors, as they are phylogenetically distant from them and are insensitive to classical non-selective opioid receptor antagonists (e.g. naloxone). Nevertheless, accumulating reports suggest that these receptors may be interesting alternative targets, especially for the development of safer analgesics. Five of these opioid peptide-binding receptors belong to the family of G protein-coupled receptors (GPCRs)—two are members of the Mas-related G protein-coupled receptor X family (MrgX1, MrgX2), two of the bradykinin receptor family (B1, B2), and one is an atypical chemokine receptor (ACKR3). Additionally, the ion channel N-methyl-D-aspartate receptors (NMDARs) are also activated by opioid peptides. In this review, we recapitulate the implication of these alternative receptors in opioid-related disorders and discuss their unconventional biology, with members displaying signaling to scavenging properties. We provide an overview of their established and emerging roles and pharmacology in the context of pain management, as well as their clinical relevance as alternative targets to overcome the hurdles of chronic opioid use. Given the involvement of these receptors in a wide variety of functions, including inflammation, chemotaxis, anaphylaxis or synaptic transmission and plasticity, we also discuss the challenges associated with the modulation of both their canonical and opioid-driven signaling.
Citation
Palmer, C. B., Meyrath, M., Canals, M., Kostenis, E., Chevigné, A., & Szpakowska, M. (2022). Atypical opioid receptors: unconventional biology and therapeutic opportunities. Pharmacology and Therapeutics, Article 108014. https://doi.org/10.1016/j.pharmthera.2021.108014
Journal Article Type | Review |
---|---|
Acceptance Date | Feb 27, 2021 |
Online Publication Date | Oct 5, 2021 |
Publication Date | May 1, 2022 |
Deposit Date | Nov 19, 2021 |
Publicly Available Date | Nov 19, 2021 |
Journal | Pharmacology and Therapeutics |
Print ISSN | 0163-7258 |
Electronic ISSN | 1879-016X |
Publisher | Elsevier |
Peer Reviewed | Peer Reviewed |
Article Number | 108014 |
DOI | https://doi.org/10.1016/j.pharmthera.2021.108014 |
Keywords | Pharmacology (medical); Pharmacology |
Public URL | https://nottingham-repository.worktribe.com/output/6738548 |
Publisher URL | https://www.sciencedirect.com/science/article/pii/S0163725821002163?via%3Dihub |
Files
Atypical opioid receptors: unconventional biology and therapeutic opportunities
(702 Kb)
PDF
Publisher Licence URL
https://creativecommons.org/licenses/by/4.0/
You might also like
Key phosphorylation sites for robust β-arrestin2 binding at the MOR revisited
(2024)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2025
Advanced Search